Misplaced Pages

5-MeO-AET

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
(Redirected from 5-MeO-αET) Chemical compound
This article relies largely or entirely on a single source. Relevant discussion may be found on the talk page. Please help improve this article by introducing citations to additional sources.
Find sources: "5-MeO-AET" – news · newspapers · books · scholar · JSTOR (July 2022)
Pharmaceutical compound
5-MeO-AET
Legal status
Legal status
  • DE: NpSG (Industrial and scientific use only)
  • UK: Class A
Identifiers
IUPAC name
  • 1-(5-methoxy-1H-indol-3-yl)butan-2-amine
CAS Number
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC13H18N2O
Molar mass218.300 g·mol
3D model (JSmol)
Melting point201 to 203 °C (394 to 397 °F)
SMILES
  • CCC(N)Cc2cc1ccc(cc12)OC
InChI
  • InChI=1S/C13H18N2O/c1-3-10(14)6-9-8-15-13-5-4-11(16-2)7-12(9)13/h4-5,7-8,10,15H,3,6,14H2,1-2H3
  • Key:JHTPCKWBFLMJMQ-UHFFFAOYSA-N
  (what is this?)  (verify)

5-Methoxy-α-ethyltryptamine (5-MeO-α-ET) is a psychoactive drug and member of the tryptamine chemical class. It reportedly produces psychedelic and stimulant effects.

Dosage

5-MeO-α-ET, when used recreationally, is usually taken orally at dosages of 50–75 mg.

Effects

5-MeO-α-ET produces entactogenic and stimulant effects that can last 4–6 hours. However, little information exists on the psychopharmacological effects of this compound, thus considerable variation with regard to dosage and effects can be expected.

Dangers

There have been no reported deaths or hospitalizations from 5-MeO-α-ET, but its safety profile is unknown.

Legality

5-MeO-α-ET is unscheduled and uncontrolled in the United States, but possession and sales of 5-MeO-α-ET could be prosecuted under the Federal Analog Act because of its structural similarities to α-ET and α-MT.

See also

References

  1. Deluca P, Davey Z, Corazza O, Di Furia L, Farre M, Flesland LH, et al. (December 2012). "Identifying emerging trends in recreational drug use; outcomes from the Psychonaut Web Mapping Project". Progress in Neuro-Psychopharmacology & Biological Psychiatry. 39 (2). Elsevier BV: 221–226. doi:10.1016/j.pnpbp.2012.07.011. PMID 22841965. S2CID 22296279.
Empathogens/entactogens
Phenylalkyl-
amines

(other than
cathinones)
Cyclized phenyl-
alkylamines
Cathinones
Tryptamines
Chemical classes
Hallucinogens
Psychedelics
(5-HT2A
agonists)
Benzofurans
Lyserg‐
amides
Phenethyl‐
amines
2C-x
25x-NBx
25x-NB
25x-NB3OMe
25x-NB4OMe
25x-NBF
25x-NBMD
25x-NBOH
25x-NBOMe
Atypical structures
25x-NMx
N-(2C)-fentanyl
3C-x
4C-x
DOx
HOT-x
MDxx
Mescaline (subst.)
TMAs
  • TMA
  • TMA-2
  • TMA-3
  • TMA-4
  • TMA-5
  • TMA-6
Others
Piperazines
Tryptamines
alpha-alkyltryptamines
x-DALT
x-DET
x-DiPT
x-DMT
x-DPT
Ibogaine-related
x-MET
x-MiPT
Others
Others
Dissociatives
(NMDAR
antagonists)
Arylcyclo‐
hexylamines
Ketamine-related
PCP-related
Others
Adamantanes
Diarylethylamines
Morphinans
Others
Deliriants
(mAChR
antagonists)
Others
Cannabinoids
(CB1 agonists)
Natural
Synthetic
AM-x
CP x
HU-x
JWH-x
Misc. designer cannabinoids
D2 agonists
GABAA
enhancers
Inhalants
(Mixed MOA)
κOR agonists
Oneirogens
Others
Serotonin receptor modulators
5-HT1
5-HT1A
5-HT1B
5-HT1D
5-HT1E
5-HT1F
5-HT2
5-HT2A
5-HT2B
5-HT2C
5-HT37
5-HT3
5-HT4
5-HT5A
5-HT6
5-HT7
Monoamine releasing agents
DRAsTooltip Dopamine releasing agents
NRAsTooltip Norepinephrine releasing agents
SRAsTooltip Serotonin releasing agents
Others
See also: Receptor/signaling modulatorsMonoamine reuptake inhibitorsAdrenergicsDopaminergicsSerotonergicsMonoamine metabolism modulatorsMonoamine neurotoxins
Tryptamines
Tryptamines
N-Acetyltryptamines
α-Alkyltryptamines
Triptans
Cyclized tryptamines
Isotryptamines
Related compounds
Categories: